PDCD1LG2 and hepatocellular carcinoma: However, overall survival of advanced-stage HCC patients with PD–L1+PD–L2+CD14+ cells was significantly shorter than similar patients with other types of CD14+ cells (p = 0.0393; Fig. 3b).